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haamatoc~ w~e cell count ONCC)) in 64 paUents (43 male; mean age 63.2 years, s.d. 8.9) admitted with acute stroke (ictus onset < 12 hours). Levels of these madrms and blood pressures (BPs, mmHg) were compared to 21 healthy controls (age 6t .5 years, s.d. 11.7). Our results are shown in the table.
There were no significant differences in these markers and BPs between patients who were alive or dead (n = 13) aner 6 months followup. Plasma viso0sity was sinif~ cormtatad to fibrinogen (r = 0,5,p < 0.001) and vWf (r = 0.3, p = 0.04). Stepwise mul~ple regression analysis demonstrated that faxinogen a.d diasfoli~ UPs were predictors for plasma viscosity (p = 0,018). Onty the WGC level was a pre~ctor for flbrinogen levels (p = 0.03). There were no s'~nificaat pmo'ictsrs for vWt and P-selectin levels. Despite eady pmsentatfon (< 12 Itours) patients with acute stroke have haemorhnolngical abhorrences (l~odnogen, WCG and plasma viscosity), ptatofot dysfunoUan (with raised P-seio~Jn) and endothelial dysfunction (with high vWf), Tilase abnormalities may act synergistically in the p~thogenasis of acute stroke and its complications, PHARMACOLOGY-BASIC 
~wology Branch, NHLBI, Bethasda, MD
Bask= flbreblast growth factor (bFGF), an angiogenic growth factor, is currently the subject of a Phase I clinical thai in pts wiih ischemic heart disease (IHD). In a Canine model of single vessel coronary occlusion, we previously demonstrated that bFGF enhances collateral blood flow (CBF) when given as a daily I.C, bolus for 4 weeks, or as a deJly left atrial bolus for 7 days; however, these schedules and mutes of administration would not be practl~ cal in pts with IHD. To establish a feasible mute of drug delivery and to limit potential systemic toxicity, we determined whether injection of bFGF into the left main coronary artoly would enhance CBR A second aim was to astab. fish the minimum effective course of bFGF b'eatment. Dogs were subjected to amemkHnducod occlusion of the left circumflex nsmnary adew. SubseqUeotly, the dogs undelwent cardiac cathatedza~on and were randomized to receive bFGF 0.1 mg/kg as a bolus into the left main coronmy artery twice (14 and 16 days after amereid placement, n = 10) or once (day 16, n = 8), A control group received the vehicle (n = 10), CBF was assessed dudng maximal coronaq/vasodilatation with radiolsheled microsphems on day 33, Maximal CBF in dogs ~ received bFGF twice was 2.39 :E 0.09 ml/min/g, exceeding that of control dogs by 39=/0 (1.72 :E 0.13 ml/miNg, mean :E SE; P < 0.0005), Dogs that received a single dose Of bFGF had an intermediate flow (2.10 :E 0.21 ), statistically indistinguishable from the other gmupe. Thus, two doses of bFGF administered into the left main coronary anery were suf~ fioient to improve CBF, an inteprention that is feasible in pts with IHD, These data provide the basis for a tdal of inIJracomnaty bFGF in pts with IHD. The impodant role of hemestatic disorders has been Increasingly recognized in patients with myocardial ischemia. NPG 15669 is a member of the leumadins, and inhibits leukocyte adhesion to the endothniium by blockage of Mac-1 upregulalion. The effects of NPC 15669 supplementation on the hemostatfo profile dedng myocazdial stunning (MS) are poorly understood. Thus, the puq~ese of this project was tO link potential changes in hamestalJc profile with NPC 15669 therapy dudng mild MS in in v/vo anin~ ntodel. Twelve opeo<dlasted Yorkshire swine underwent LAD occlusion for 8 minutes followed by 90 minutes of reperfusion. Blood samples were obtained at baseline, at 4 and at 8 minutes of OcClusion, and at 60 ~',d 90 minutes of reped~Jsion, NPC 15669 (10 mg/kg loading dose followed by constant infusion at 6 rag/k9 -1/11 -t) was administered in 6 animals; another 6 swine received saline end served as conlmls. Coneenlmtions of antithrombth-III (AT-Ill), Protein C, total Protein S, ftb~ne~n, endothniin-t lET-l), as well as the stable metabulitss of thmmboxane (TxB~) and prostacydin (6-keto-PGFI=), were measured in the systemic cin~l~ion, Treatment with NPC 15669 was assedalsd with diminished ETol (37,4%), 6-kato-PGFla (47.1%) levels and inornased fibmno~in (77.6%) concentrations during MS, There were no changes in the plasma cenceatrations of TxB.z, total protein S, protein C and AT-Ill in NPC 15669 group when compared with controls.
Mild MS ts as~sociatsd with sobstantial dynamio changes in the hanlestatfo profile. NPC 15669 administration in a swine model of MS alfe¢ls spenif'¢ hemostatls parameters. This data provl~s slrong support for the involvement During 40 months average follow-up, fatal or non.fatal MI occurred in 11.5% of the 845 patientS on CCB dudng follow-up versus 7.5% of the 255t patients not on CCB (,0 ~= 0.001, O.R. 1.6195% Cl 1.24-2,07) in the enalupdl group; and in 14.4% of the 874 patients on CCB versus 9,3% of the 2527 patients not on CCB (p = 0.001, O,R. 1.64; CI 1.30-2.06) in the placebo group, By multivariate Cox regression analysis, adjus~ng for 29 variables descchlog demographics, Gomorblddy, e~oiooy and sovedty of LVD, head failure, and cancomitont drug use, CCB use dudng follOw-up was an independent predictor of increased dsk (R.R. 1.37; CI 1.14-1.63),
The increased dsk associated with CCB was also observed when the combined endpoint of MI, cardiac death, or hospitalization for angina was considered. The incrcased MI risk was obsen/ed whether CCB were used both at baseline and follow-up or only at follOw-up. In addition, the risk was higher when the mean follow-up heart rate Of pa~ents on CCB was higher than the median follow-up rate of patients on CCB (74 beats/minoto).
In contrast~ using the same database and analysis, beta 104od,,m use was assodated with a lower rate of fatal or non-fatal MI (multivariate Cox R.R. 0.80; Cl 0.61-1.05).
In this relmspactive analysis of patients with LVD, CCB use was associated with significantly increased risk of MI. Thmmbi that form as a result of defective endogenous Iti0dnolysis may be most sensitive to thmmbolylic agents, Impaired flbfinolytic activity has been aSSociated with low plasma levels of single.d~ln urokinase (scu-PA), raised I~lxotoin(a) [Lp(a)] and, paradoxically, high t-PA enSgen.
We invest.~gated the relation between endogenous fibdrmlytic factors on admission and subsequent efficacy of thrombolytio therapy in 51 patients with acute myocardial infarction (AMI) boated within 6 h of symptoms with intravenous rt-PA (20-60 MU) and hepadn, Pm-traatment plasma concentrations of Lp(a) (mg/dl), t-PA antigen lug/L) and urokinase (U-PA, ug/L) were measured by ELISAs and of scu-PA lug/L) by bioimmunoassay. A coronary artedogram was performed 90 min after the start of lytic therapy. Pedusion of the infamt-artsry was defined as TIMI grade 3, At 90 rain, a TIMI 3 infarot-erfory was found in 27 pts, The perfosed v,3 o4:~uded-artew pts did not differ significantly in age, sex, smoking stslus, delay to treatment, time of day of therapy Or rt-PA dose at 90 min. Plasma factors (median and interquariffes) were: Lp(a) t-PA scu.PA u-PA Perfused 16 (11-~2) 26 (17-~) t.9 (1.6--2,1) 2,7 (P-2-,3) Occluded 9 (5-27) 15 (10-P.1) P,l(1.g-2.6) 2.6 (2.4-2.8) p value 0,02 0.003 0.03
0,38
Thus, in patients with AMI receiving rt-PA, early coronary mperfusion, cony pared with persistent occlusion, is associat~l with higher plasma Lp(a) and t-PA antigen levels and lower plasma scu-PA on admission. Phannacotsgical doses of rt*PA thus appear most effective when naturalflbdnatysls is def'cteot. We have examined the alfect of continuous infusion of prostacyclin (PGI~)
